Drug Trial Radar · NCT04335682
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
111
Actual
Start
Aug 17, 2021
Primary completion
Sep 1, 2025
Study completion May 1, 2026
Sponsor
- Lead sponsor
- Alliance Foundation Trials, LLC.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bayer
- First posted
- Apr 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, randomized, open-label phase II study comparing cognitive outcomes between men with metastatic and non-metastatic castration resistant prostate cancer (CRPC) or metastatic hormone sensitive prostate cancer (HSPC). Approximately 132 patients will be enrolled. Eligible patients will be randomized in a 1:1 fashion to treatment with enzalutamide 160 mg orally daily or darolutamide 600 mg orally twice daily, in combination with standard LHRH agonist based treatment. Cognitive assessments will be performed using modules from Cambridge Neuropsychological Test Automated Battery (CANTAB) an internationally recognized software for assessing cognitive function and impairment.
Conditions
- Metastatic Prostate Cancer
- Prostate Cancer Metastatic
- Prostate Cancer
- Castrate Resistant Prostate Cancer
- Hormone Sensitive Prostate Cancer
- Non-metastatic Prostate Cancer
Interventions
DarolutamideDrug
Patients randomized to darolutamide.
EnzalutamideDrug
Patients randomized to enzalutamide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the Maximally Changed Cognitive DomainTime frame: 24 weeks
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
University of California - San Francisco at Mount Zion
San Francisco, California
Northwestern University Feinberg School of Medicine
Chicago, Illinois
University of Chicago
Chicago, Illinois
University of Kansas Cancer Center
Fairway, Kansas
Dana Farber Cancer Institute
Boston, Massachusetts
University of Minnesota
Minneapolis, Minnesota
University of Oklahoma
Oklahoma City, Oklahoma
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.